Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Hunan Province Tumor Hospital

Status: Enrolling

Conditions: Non Small Cell Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04324151

PERSPECT

Details and patient eligibility

About

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Full description

Inclusion criteria:

diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT

Enrollment: 70 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
• Potentially Resectable NSCLC
• Treatment Plan is Crizotinb or Standard Chemotherapy

Exclusion criteria

• Patients with contraindication of chemotherapy
• Pregnant or breast feeding women